IGM Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

IGM Biosciences CEO'su Mary Harler, Oct2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.58% doğrudan sahiptir ve bu hisselerin değeri $ 2.36M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 6.2 yıldır.

Anahtar bilgiler

Mary Harler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.6%
Yönetim ortalama görev süresi	3.1yrs
Yönetim Kurulu ortalama görev süresi	6.2yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Jan 05

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

Sep 23

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

Aug 29

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

Aug 08

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Jun 09

IGM Biosciences: Interesting Science, Poor Trial Data

Feb 23

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?

Feb 17

Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Sep 07

IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

May 25

CEO

Mary Harler (59 yo)

less than a year

Görev süresi

Ms. Mary Beth Harler, M.D. is the Chief Executive Officer of IGM Biosciences, Inc. since October 01, 2024 and serves as its Director. She had been Head of Research & Autoimmunity at IGM Biosciences, Inc. s...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mary Harler	CEO & Director	less than a year	Veri yok	0.58% $ 2.4m
Misbah Tahir	Chief Financial Officer	6yrs	US$1.08m	0.037% $ 150.5k
TS Harigopal	Senior Vice President of Group Operations	2yrs	Veri yok	Veri yok
Steven Weber	Senior VP	2.8yrs	Veri yok	0.0054% $ 21.8k
Paul Graffagnino	Senior Vice President of Legal Affairs	4yrs	Veri yok	Veri yok
Suzette Tauber	Chief Human Resources Officer	5.6yrs	Veri yok	Veri yok
Angus Sinclair	Executive Vice President of Research	3.4yrs	Veri yok	Veri yok
Lisa Decker	Chief Business Officer	3.8yrs	US$4.92m	0.032% $ 127.5k
Marvin Peterson	Executive Vice President of Process Development & Manufacturing	3.8yrs	Veri yok	Veri yok
Elizabeth Haanes	Senior Vice President of Intellectual Property	2.8yrs	Veri yok	Veri yok
Elaine Sapinoso	Senior Vice President of Quality	2yrs	Veri yok	Veri yok
Faraz Siddiqui	Senior Vice President of Manufacturing Operations	1.4yrs	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: IGMS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mary Harler	CEO & Director	no data	Veri yok	0.58% $ 2.4m
Felix Baker	Independent Director	4yrs	US$168.55k	0.0037% $ 15.1k
M. Behrens	Independent Director	6yrs	US$178.30k	0.69% $ 2.8m
Mark Davis	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Rafi Ahmed	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Lee	Independent Director	5.5yrs	US$166.09k	0.019% $ 75.2k
Jakob Topsoe	Independent Director	6.4yrs	US$166.09k	0.15% $ 612.4k
Julie Hambleton	Independent Director	6.4yrs	US$204.09k	0.0034% $ 13.6k
Christina Topsoe	Independent Director	6.4yrs	US$175.84k	0.10% $ 418.0k
William Strohl	Independent Director	6.4yrs	US$236.59k	0% $ 0
Elizabeth Thompson	Independent Director	1.3yrs	US$167.54k	0.0098% $ 39.5k
Gordon J. Freeman	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

6.2yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IGMS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.2 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/08 23:08
Gün Sonu Hisse Fiyatı	2025/01/08 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

IGM Biosciences, Inc. 15 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Etzer Darout	BMO Capital Markets Equity Research
Geoffrey Meacham	BofA Global Research
Charlie Yang	BofA Global Research

IGM Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

IGM Biosciences, Inc. Announces Chief Executive Officer Changes

Independent Director notifies of intention to sell stock

IGM Biosciences, Inc., Annual General Meeting, Jun 11, 2024

CEO, President & Director recently sold US$90k worth of stock

Insufficient new directors

IGM Biosciences, Inc. Announces Board Changes

Recent updates

Consensus revenue estimates increase by 16%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Consensus revenue estimates decrease by 74%

Price target decreased by 13% to US$19.10

IGM Biosciences, Inc. Announces Chief Executive Officer Changes

IGM Biosciences: Waiting For Godot

Consensus revenue estimates increase by 281%

Consensus revenue estimates fall by 95%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

IGM Biosciences, Inc. Provides Pipeline Updates

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Consensus revenue estimates increase by 1,210%

IGM Biosciences: Unlikely To Move The Needle Again In 2024

First quarter 2024 earnings released: US$0.83 loss per share (vs US$1.33 loss in 1Q 2023)

IGM Biosciences, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?

IGM Biosciences, Inc., Annual General Meeting, Jun 11, 2024

New major risk - Share price stability

CEO, President & Director recently sold US$90k worth of stock

Consensus EPS estimates upgraded to US$3.26 loss

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

Igm Biosciences, Inc. to Reduce its Workforce by Approximately 22%

Consensus revenue estimates decrease by 13%, EPS upgraded

We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

IGM Biosciences, Inc. Announces Board Changes

Price target decreased by 7.8% to US$30.09

New minor risk - Shareholder dilution

IGM Biosciences, Inc. announced a financing transaction

IGM Biosciences, Inc. Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

Consensus revenue estimates decrease by 43%, EPS upgraded

We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn

Consensus revenue estimates decrease by 50%

Price target decreased by 17% to US$32.64

IGM Biosciences Initiates First-In-Human Clinical Trial of Igm-7354 in Solid Tumors

IGM Biosciences Announces Update on Igm-8444 Phase 1 Trial and Future Clinical Development

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

CEO, President & Director recently sold US$235k worth of stock

CEO, President & Director notifies of intention to sell stock

Independent Director recently bought US$1.0m worth of stock

Insufficient new directors

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer exercised options and sold US$548k worth of stock

Independent Chairman of the Board recently bought US$140k worth of stock

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

Chief Scientific Officer exercised options and sold US$460k worth of stock

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

Chief Scientific Officer exercised options and sold US$531k worth of stock

Price target decreased to US$43.78

Consensus revenue estimates fall by 98%

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

Insufficient new directors

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

IGM Biosciences, Inc. Appoints Steven Weber as Principal Accounting Officer

Independent Director recently bought US$234k worth of stock

Consensus revenue estimates fall by 86%

Price target decreased to US$52.78

Chief Scientific Officer exercised options and sold US$60k worth of stock

Independent Director recently bought US$1.4m worth of stock

Price target decreased to US$52.78

Chief Scientific Officer exercised options and sold US$207k worth of stock

Price target decreased to US$57.89

IGM Biosciences: Interesting Science, Poor Trial Data

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?